Image not available in RecallScope.
Towa Pharmaceutical "Loxoprofen Na Tape 50mg ‘Towa’" and 3 other products - Recall
Official notice
15 Jul 2026
Last checked
27 Oct 2026
An official CAA Japan notice concerns Towa Pharmaceutical "Loxoprofen Na Tape 50mg ‘Towa’" and 3 other products - Recall. Manufacturing and process controls were found to have been performed using methods differing from those in the approval document, and deficiencies in records were identified. Reason for recall: At the contract manufacturer for these products, manufacturing and process controls were found to have been performed using methods differing from those in the approval document, and deficiencies in records were identified. It was therefore determined that product quality could not be adequately assured, and a voluntary recall will be conducted. Specific potential health effects: Stability test results and test results for retained samples and other samples within their expiration dates have confirmed that product quality is unaffected. Consequently, safety and efficacy are unaffected, and serious health effects are not considered likely. No health effects related to this matter have been reported to date. Published 2026-07-15.
What to do now
All pharmaceutical wholesalers and other recipients supplied with the affected lots have been identified. They will be notified of the recall in writing, and the products will be recalled.
Recall number
2-12890
Official notice
2026-07-15
The hazard
The hazard
Manufacturing and process controls were found to have been performed using methods differing from those in the approval document, and deficiencies in records were identified. Reason for recall: At the contract manufacturer for these products, manufacturing and process controls were found to have been performed using methods differing from those in the approval document, and deficiencies in records were identified. It was therefore determined that product quality could not be adequately assured, and a voluntary recall will be conducted. Specific potential health effects: Stability test results and test results for retained samples and other samples within their expiration dates have confirmed that product quality is unaffected. Consequently, safety and efficacy are unaffected, and serious health effects are not considered likely. No health effects related to this matter have been reported to date.
How to check if you're affected
How to check if you're affected
Compare the product name and identifiers below with the item you own. Check the official notice for the affected products and next steps.
Recall Numbers
Checked manually this time?
Follow brands and keywords in the app to receive alerts for matching official notices.
Turn on recall alertsAffected products
Affected products
Product 1
Hazard
Where it was sold
Where it was sold
Retailer information is not currently available in RecallScope. Check the official notice for distribution details.
Location 1
Affected area 1
Company & contacts
Company & contacts
Brand
Manufacturer
Phone
Brand: 東和薬品. Contact: 東和薬品株式会社 学術部DIセンター. Phone 0120-108-932.
Source & status
Source & status
Recall details
Recall details
Recall number
Event id
Source tier
Documents, notices & source
See the official notice and source documents for full details.
View full official noticeWeekly recall digest
Get next week's recalls before you need them.
One email every Monday — official-source recalls for your country, and nothing else. Unsubscribe from any email.
The digest arrives once a week. For matching recall alerts after notices are processed, get the app.
This recall was published 15 Jul 2026. The next one won't wait for you to search.
RecallScope checks listed publishers for the brands and VINs you follow, and can alert you when a matching notice is processed.
